News

year
press release

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

read more
press release

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

read more
press release

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

read more
press release

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

read more
press release

Monte Rosa Therapeutics Announces Leadership Team Promotions

read more
press release

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

read more
press release

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

read more
press release

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

read more
press release

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

read more
press release

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

read more
press release

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

read more
press release

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

read more
press release

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

read more
press release

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

read more
press release

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

read more
press release

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

read more
press release

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

read more
press release

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

read more
press release

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

read more
press release

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

read more
press release

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

read more
press release

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

read more
press release

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

read more
press release

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

read more
press release

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

read more
press release

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

read more
press release

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

read more
press release

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

read more
press release

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

read more
press release

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

read more
press release

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

read more
press release

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

read more
press release

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

read more
press release

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

read more
press release

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

read more
press release

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

read more
press release

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

read more
press release

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer

read more
press release

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

read more
press release

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

read more
press release

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

read more
press release

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

read more
press release

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

read more
press release

Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer

read more
press release

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

read more
press release

Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments

read more
press release

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

read more
press release

Monte Rosa Therapeutics Expands Senior Management Team

read more
press release

Monte Rosa Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

read more
press release

Monte Rosa Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

read more
press release

Monte Rosa Therapeutics Announces Formation of Scientific Advisory Board

read more
press release

Monte Rosa Therapeutics Strengthens Executive Leadership Team with New Appointments

read more
press release

Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform

read more
press release

Monte Rosa Therapeutics Discloses $32.5 Million Financing

read more
press release

Versant Ventures Strengthens Global Team and Discovery Engine Infrastructure

read more